Diagnostic challenges and therapeutic strategies for large-cell neuroendocrine carcinoma of extrahepatic bile ducts: A rare case report

肝外胆管大细胞神经内分泌癌的诊断挑战和治疗策略:一例罕见病例报告

阅读:1

Abstract

RATIONALE: Large-cell neuroendocrine carcinoma (LCNEC) of the extrahepatic bile duct (EHBD) is an exceedingly rare malignancy with few documented cases, presenting significant diagnostic and therapeutic challenges. This case highlights the complexities in managing this aggressive tumor, the essential role of multidisciplinary collaboration, and the ongoing debates regarding the necessity of adjuvant therapy. It underscores the need for biomarker-guided strategies. PATIENT CONCERNS: A 75-year-old male presented with a 2-week history of jaundice, pruritus, dark urine, nausea, and vomiting. Laboratory findings revealed severe cholestasis, with a total bilirubin level of 179.2 μmol/L, and elevated CA19-9, measured at 457.36 U/mL. DIAGNOSES: Abdominal magnetic resonance imaging revealed a 1.4 cm hilar bile duct mass with malignant characteristics. Postoperative histopathological analysis confirmed a 1.5 cm tumor consisting of 90% poorly differentiated LCNEC, with a Ki-67 index of 80% and a PD-L1 combined positive score of 5. The tumor exhibited vascular invasion, neural infiltration, and metastasis to 2 lymph nodes. INTERVENTIONS: A multidisciplinary team (MDT) directed preoperative biliary drainage and performed a laparoscopic radical resection. Despite the presence of high-risk features, the patient declined adjuvant chemotherapy. OUTCOMES: Six months post-surgery, an enhanced abdominal magnetic resonance imaging scan revealed intrahepatic metastases. Consequently, the patient commenced chemotherapy with a combination of cisplatin and etoposide. LESSONS: This case underscores the aggressive nature of LCNEC of the EHBD and the crucial role of MDT-driven surgical intervention. The rapid recurrence suggests the necessity for postoperative adjuvant therapy; however, standard treatment protocols are lacking due to insufficient evidence from evidence-based medicine, highlighting the need for biomarker-driven strategies. The rarity of these tumors renders standardized management elusive, necessitating global collaboration to refine diagnostic and therapeutic frameworks.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。